Progyny, Inc. (PGNY) Earnings Call Transcripts

Progyny, Inc.'s Latest Earnings Call - May 21, 2026

Progyny, Inc. reported strong financial results for the fiscal year 2025, achieving record revenue of $1.29 billion and adjusted EBITDA of $222 million, both reflecting double-digit growth over 2024. The company also generated $210 million in operating cash flow, marking a 17% increase year-over-year. Management expressed confidence in continued momentum into 2026, supported by a nearly 100% client retention rate and a favorable pipeline for new business, although no specific revenue guidance was provided for the upcoming year.

Reported metrics

Guidance from management

Management did not provide specific revenue guidance for 2026 but expressed confidence in continued growth and momentum based on strong operational performance and pipeline strength.

What management said

I have at this meeting a complete list of the stockholders of record of our common stock on March 27, 2026, the record date for this meeting. This list is available for viewing and has been available for inspection for the past 10 days at 1359 Broadway, second floor, New York, New York. I also have an affidavit certifying that on April 10, 2026, and A notice of Annual Meeting of Stockholders of Progyny was deposite...

At this time, I'd like to introduce Kayla Walsh of Computershare, who has been appointed to act as Inspector of Election at this meeting. Ms. Walsh has taken and subscribed the customary oath of office to execute her duties with strict impartiality. We will file this oath with the records of the meeting. Her function is to decide upon the qualifications of voters, accept their votes and when balloting on all matter...

What analysts pressed on

Analysts raised concerns regarding the potential impact of rising medical costs on Progyny's pricing strategy and overall profitability. There was also a question regarding the use of GAAP net income in future compensation targets, indicating a desire for more transparency in financial metrics.

Main topics on the call

• Record Financial Performance — Progyny achieved record highs in revenue and adjusted EBITDA, reporting $1.29 billion and $222 million respectively for 2025, with both metrics increasing by double digits over 2024. Management stated, '2025 was an excep...
• Client Retention and Expansion — The company reported a near 100% retention rate of existing clients for 2026, with 30% of the overall client base expanding their Progyny programs. This reflects strong client satisfaction and operational excellence.
• Cost Management Success — Progyny highlighted its ability to control cost trends, stating that its rates have increased at a rate over 5x lower than the 27% compounded increase in overall medical costs since 2022. This positions them favorably ag...
• Pipeline Strength — Management indicated a 'substantially favorable' pipeline compared to the previous year, with strong activity from RFPs and early favorable notifications from large clients. This suggests robust demand for Progyny's serv...

Read the full Progyny, Inc. transcript (May 21, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 57 Progyny, Inc. earnings call transcripts on record, spanning January 13, 2020 to August 6, 2026. Based on this history, Progyny, Inc. reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

PGNY

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Health Care Providers and Services

Calls on record

57

First call

January 13, 2020

Most recent

August 6, 2026

Reporting cadence

quarterly